Panzem

Panzem is an oral small‑molecule formulation of 2‑methoxyestradiol, an endogenous 17β‑estradiol metabolite developed by EntreMed as an antineoplastic and antiangiogenic agent. At pharmacologic concentrations, 2‑methoxyestradiol disrupts microtubule polymerization, induces apoptosis, and inhibits angiogenesis, in part through effects on hypoxia‑inducible factor‑1α and other proliferative signaling pathways.[3][7][15] Panzem has been advanced primarily in oncology as Panzem capsules and an enhanced‑bioavailability NanoCrystal Dispersion (Panzem NCD), with clinical evaluation in refractory solid tumors, multiple myeloma, glioblastoma multiforme, and metastatic renal cell carcinoma, but its clinical development has been limited by pharmacokinetic challenges and ultimately halted despite obtaining multiple FDA orphan drug designations.[2][3][5][6][7][14][15]

Brand names

PanzemPanzem NCD

Other names

2-methoxyestradiol2ME22-methoxy-17β-estradiol